🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Updated guidance on reversal of direct oral anticoagulants, recent studies of antidotes, prothrombin complex concentrates, agents under investigation, FXI inhibitors & monitoring. Jerrold Levy, MD Joseph R. Shaw   @connors_md Deborah Siegal  Special 🙏 Saskia Middeldorp jthjournal.org/article/S1538-…

Truly honored to contribute to ATVB: An AHA Journal's Centennial Collection with mentor extraordinaire Denisa Wagner: our thoughts on targeting #NETs in #DVT, 10 years following our "Tangled up in NETs" review. Stay tuned for more on this from us soon 🕸️🩸💉bit.ly/3LJnV4g

Happy to see our work on novel therapeutic strategies targeting #thromboinflammation in venous thromboembolism featured in JACC Journals 🧯🔥🩸 Marc Carrier AntonioAbbate Marcello Di Nisio @YogenKanthi #cvCoag #CardioTwitter #VTE

To use or not to use reversal agents for DOACs? 🤔 Not all DOAC-associated bleeds require reversal. This table summarizes guidance from ISTH SSC on this issue ✍️Jerrold Levy, MD Lana Castellucci @connors_md Deborah Siegal Read this important paper at jthjournal.org/article/S1538-…

Kicking off #WorldThrombosisDay in Pescara, 🇮🇹! Come visit us! #StopTheClot #WTDay24 Marcello Di Nisio Matteo Candeloro Ud'A World Thrombosis Day

Excellent overview of clinical trials (completed and ongoing) of anti-inflammatories in cardiovascular disease ahajournals.org/doi/abs/10.116… ATVB: An AHA Journal

📍New editorial from the ISTH Early Career Committee highlighting the importance of interdisciplinary collaboration and its opportunities within the thrombosis and hemostasis field. 🔖 #ISTHEarlyCareer Sarah Sewaralthahab, MD, MPH, ABIM Shrey Kohli Becky Zon, MD Aaron Iding Nicola Potere

📌#ASH24. 🔜🔔Looking forward to discussing #thromboinflammation of #cancer associated #thrombosis‼️ Join us today from 2:00pm PT Jeff Zwicker, MD @Lbkreuziger Lalitha Nayak Ang Li, MD, MS Marisa Brake, PhD Joan D. Beckman & other outstanding presenters

Nice dinner with the future generation of clinical researchers in thrombosis at #ASH24. From BSc and MSc to medical student and thrombosis fellow. The future is bright ⭐️Feel free to stop by their posters or attend their presentations to generate a good academic discussion!

Worse performance status (PS) seems to be associated with an ⬆️ risk of bleeding and mortality among patients with cancer receiving primary thromboprophylaxis. Nicola Potere showed the ECOG-PS may help with risk stratification and could be used to help decision making #ASH24

Cisplatin induces platelet pyroptosis via the activation of the caspase-3–GSDME axis. ow.ly/aFLl50Uv02m #plateletsandthrombopoiesis #thrombosisandhemostasis

Thrilled to join the Journal of Cardiovascular Pharmacology Journal of Cardiovascular Pharmacology Thankful for the trust and opportunity George W. Booz AntonioAbbate Giuseppe Biondi-Zoccai

Honored, thrilled, thankful for the opportunity — 🔥#thromboinflammation (NLRP3/IL-1) & #VTE 🩸— such an exciting field harbouring transformative discoveries and soon therapeutic advances🌟 🎥 soon available at: canvector.ca Thank you CanVECTOR Network Joseph R. Shaw ++

Congratulations to Dr. Deborah Siegal for being this year’s national winner of a “young investigator award” from the Canadian Society for Clinical Investigation (CSCI). 🏆 “I am fortunate to be a part of Ottawa's world-class medical research hub which has helped me expand the scope

It’s #BloodClotAwarenessMonth. Do your patients know the signs and symptoms of blood clots? Encourage them to learn more about blood clots at getouttheclot.com/patient/ #VTEAwareness #ISTH

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Presented at #ACC25: In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results:

Practice-changing paper in @nejm by Mahé Isabelle Marc Carrier API-CAT team proves that apixaban dose can be reduced after 6mo of anticoag rx with no loss of efficacy and less bleeding. Congrats to the team! nejm.org/doi/full/10.10…